WM-8014: Selective KAT6A/B Inhibitor for Epigenetic Drug Target Research

Executive Summary: WM-8014 is a potent, selective, reversible, and competitive histone acetyltransferase inhibitor of KAT6A/B, KAT5, and KAT7, with IC₅₀ values of 8 nM, 28 nM, 224 nM, and 342 nM respectively (APExBIO, product page). It acts by directly competing with acetyl-CoA at the substrate-binding domain, specifically the MYST domain, and does not induce general cytotoxicity while effectively causing cell cycle arrest and senescence via the p16^INK4A–p19^ARF pathway (bioRxiv, DOI). In vivo, WM-8014 reduces KRAS-driven hepatocyte overproliferation in zebrafish without affecting normal liver growth. WM-8014 is highly soluble in DMSO (≥76.1 mg/mL), but poorly soluble in water and ethanol, and requires specific storage conditions. Due to high plasma-protein binding, its in vivo application is limited to model systems, with WM-1119 recommended for mouse studies.

Biological Rationale

KAT6A (MOZ) and KAT6B (MORF/QKF) are members of the MYST family of histone acetyltransferases (HATs), which regulate chromatin structure, gene expression, and cell cycle progression. Dysregulation of KAT6A/B activity is linked to aberrant proliferation, defective senescence, and tumorigenesis in various cancers. The p16^INK4A–p19^ARF pathway is a key tumor suppressor mechanism, frequently silenced in oncogenic contexts. Selective inhibition of KAT6A/B allows researchers to dissect epigenetic control of senescence and proliferation without inducing widespread toxicity. WM-8014 provides a precision tool to probe these mechanisms in cell models and disease-relevant systems (internal article), extending mechanistic insight into the role of epigenetic drug targets in cancer biology.

Mechanism of Action of WM-8014

WM-8014 is a competitive, reversible inhibitor that selectively targets the acetyl-CoA-binding site of the MYST domain in KAT6A, KAT6B, KAT5, and KAT7. The acyl sulfonyl hydrazide moiety forms hydrogen bonds analogous to those of the diphosphate group of acetyl-CoA, effectively occupying the cofactor binding site and blocking substrate acetylation (bioRxiv). This mode of action results in potent inhibition with IC₅₀ values: 8 nM (KAT6A), 28 nM (KAT6B), 224 nM (KAT5), and 342 nM (KAT7) in biochemical assays at 25°C, pH 7.5. WM-8014 does not covalently modify the enzyme, enabling reversible binding and washout studies. Its high selectivity ensures minimal off-target effects in non-MYST family HATs or unrelated proteins.

Evidence & Benchmarks

• WM-8014 inhibits KAT6A acetyltransferase activity with an IC₅₀ of 8 nM in vitro (25°C, pH 7.5) (bioRxiv).
• RNA-seq of mouse embryonic fibroblasts (MEFs) treated with 1 μM WM-8014 for 48 hours shows upregulation of Cdkn2a mRNA and downregulation of Cdc6, a direct KAT6A target (bioRxiv).
• WM-8014 does not induce general cytotoxicity in MEFs, as measured by cell viability and LDH release assays at concentrations up to 10 μM for 72 hours (bioRxiv).
• In a zebrafish model of KRAS^G12V-driven hepatocellular proliferation, WM-8014 (0.1–1 μM, 72 hours) causes a concentration-dependent reduction in liver volume and S-phase hepatocyte entry, sparing normal liver growth (bioRxiv).
• WM-8014 is highly soluble in DMSO (≥76.1 mg/mL), but insoluble in water (>16 μM) and ethanol; recommended storage is -20°C (APExBIO).

This article builds on the analysis in WM-8014 (SKU A8779): Practical Solutions for Epigenetic Assays by providing detailed quantitative benchmarks and highlighting in vivo selectivity profiles.

Applications, Limits & Misconceptions

WM-8014 is a validated research tool for:

• Selective inhibition of KAT6A/B in cell-based models of oncogene-induced senescence.
• Cell cycle arrest and senescence pathway interrogation via p16^INK4A–p19^ARF activation.
• Epigenetic drug target validation in cancer biology research (product page).
• Mechanistic studies on acetyl-CoA site occupation and substrate selectivity.

Use in in vivo mouse models is limited due to high plasma-protein binding; the derivative WM-1119 is recommended for such studies. For high-throughput workflows, WM-8014 provides reproducible, sensitive readouts in cell viability, proliferation, and senescence assays (see also WM-8014: Reliable KAT6A/B Inhibition for Cell Assays; this article adds mechanistic context and troubleshooting advice).

Common Pitfalls or Misconceptions

• WM-8014 is not suitable for in vivo mouse studies due to high plasma-protein binding; use WM-1119 instead.
• It is not a pan-HAT inhibitor; it selectively targets the MYST family (KAT6A/B, KAT5, KAT7).
• WM-8014 is insoluble in water and ethanol; improper solvent use may cause precipitation and loss of activity.
• It does not cause general cytotoxicity; cell death observed at high concentrations may be due to off-target or solvent effects.
• Long-term storage of WM-8014 solutions (especially in DMSO at room temperature) may result in degradation.

Workflow Integration & Parameters

WM-8014 (SKU A8779) from APExBIO can be integrated into cell-based workflows for epigenetic and cancer biology research. Stock solutions should be prepared in DMSO (≥76.1 mg/mL), aliquoted, and stored at -20°C. Working concentrations in cell assays typically range from 0.1–10 μM, with careful titration recommended. For cell cycle and senescence assays, exposure times of 24–72 hours are standard. RNA-seq and qPCR can be used to monitor Cdkn2a upregulation and Cdc6 downregulation as pharmacodynamic readouts. WM-8014's reversible binding allows for washout and recovery studies. Detailed troubleshooting and protocol guidance are available in Precision KAT6A Inhibitor for Epigenetic Research, whereas the present article provides quantitative solubility and selectivity benchmarks.

Conclusion & Outlook

WM-8014 is a best-in-class, selective inhibitor for KAT6A/B, enabling precise dissection of the epigenetic regulation of senescence and proliferation. Its competitive, reversible mechanism at the acetyl-CoA site, combined with low cytotoxicity, makes it a preferred reagent for mechanistic and translational cancer research. While in vivo use in rodents is restricted, WM-8014 remains a foundational tool for cell-based and zebrafish models. For researchers seeking robust, reproducible inhibition of KAT6A/B in epigenetic workflows, the WM-8014 A8779 kit from APExBIO is a validated, widely adopted choice.